Holen Sie sich die Stockscreener-App
26.80
0.69%
0.18
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.62
Offen:
$26.66
24-Stunden-Volumen:
9.66M
Relative Volume:
0.24
Marktkapitalisierung:
$150.86B
Einnahmen:
$59.37B
Nettoeinkommen (Verlust:
$4.25B
KGV:
36.22
EPS:
0.74
Netto-Cashflow:
$8.23B
1W Leistung:
+1.38%
1M Leistung:
+1.46%
6M Leistung:
-14.61%
1J Leistung:
-0.80%
1-Tages-Spanne:
$26.58
$26.88
1-Wochen-Bereich:
$25.96
$27.07
52-Wochen-Spanne:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.81 | 150.86B | 59.37B | 4.25B | 8.23B | 0.74 |
|
LLY
Lilly Eli Co
|
814.85 | 764.20B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
84.92 | 373.06B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
152.70 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
174.74 | 309.71B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.47 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer (PFE) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Lewis Asset Management LLC Sells 22,613 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Acquired by Capital Investment Advisory Services LLC - MarketBeat
OLD National Bancorp IN Decreases Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Murphy Pohlad Asset Management LLC - MarketBeat
Drystone LLC Takes $3.87 Million Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Foster & Motley Inc. Has $3.26 Million Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Asset Dedication LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Protein Therapeutics Market is estimated to reach $566.66 Billion by 2030 | Pfizer Inc., Johnson and Johnson, - EIN News
Pfizer's SWOT analysis: pharmaceutical giant faces post-covid challenges - MSN
Pfizer director Daniel Cronin sells shares worth $20,140 - Investing.com
Petra closes fifth fund at $270m, Northwind funds Pfizer HQ conversion loan - Alternatives Watch
NYC Project to Convert Former Pfizer Headquarters Lands $135 Million Loan - MSN
Pfizer (NYSE:PFE) Trading 0.4% HigherHere's Why - MarketBeat
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Project to convert former Pfizer HQ into housing lands $135M loan - Crain's New York Business
Swedbank AB Sells 614,657 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer to pay nearly $60M over kickbacks for migraine drug developed by New Haven-based Biohaven - Hartford Business Journal
Allen Capital Group LLC Has $3.33 Million Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Purchased by Hantz Financial Services Inc. - MarketBeat
Forsta AP Fonden Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Pfizer’s Stock Plunge: A Hidden Treasure for Savvy Investors? - Jomfruland.net
Pfizer: to present its advances in oncology -January 29, 2025 at 07:20 am EST - Marketscreener.com
Barry Investment Advisors LLC Has $4.64 Million Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Perigon Wealth Management LLC Sells 14,869 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer (NYSE:PFE) Stock Price Down 0.6% on Analyst Downgrade - MarketBeat
Pregabalin Market Detailed In New Research Report 2025 | Pfizer, Novartis AG, Sanofi - openPR
Is Pfizer the Safe Stock You Should Consider Investing in for 2025? - Jomfruland.net
Is Pfizer Inc. (PFE) the Safe Stock to Buy for the Long Term in 2025? - Insider Monkey
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Nebraska joins in settling kickback allegations against Biohaven Pharmaceutical Holding Company Ltd. - News Channel Nebraska
Nebraska joins multi-state settlement against Biohaven Pharmaceutical for kickback allegations - newschannelnebraska.com
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider (NYSE:PFE) - Seeking Alpha
Pfizer Inc. (PFE): Is This Healthcare Stock A Good Buy? - Yahoo Finance
Pfizer Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Pfizer's Options: A Look at What the Big Money is Thinking - Benzinga
Pfizer (NYSE:PFE) Stock Price Down 0.6% After Analyst Downgrade - MarketBeat
Here's How to Play Pfizer Stock Before Q4 Earnings Release - Yahoo Finance
Matrix Asset Advisors Inc. NY Sells 38,127 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Patrick M Sweeney & Associates Inc. Has $2.08 Million Stake in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Next Level Private LLC - MarketBeat
Griffin Asset Management Inc. Has $2.18 Million Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Sold by Warner Financial Inc. - MarketBeat
Buffington Mohr McNeal Makes New Investment in Pfizer Inc. (NYSE:PFE) - MarketBeat
BankPlus Wealth Management LLC Buys New Shares in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium - The Bakersfield Californian
Court Place Advisors LLC Decreases Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Breast Cancer Market To Reach USD 49.2 Billion By 2032 | AstraZeneca, Pfizer Inc., Merck & Co, Sanofi, - EIN News
Pacer Advisors Inc. Raises Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Apexium Financial LP Acquires 9,570 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):